QIAGEN (QGEN)
(Delayed Data from NYSE)
$43.21 USD
-0.67 (-1.53%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.22 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.21 USD
-0.67 (-1.53%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $43.22 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Hologic Updates Breast Biopsy System to Enhance Workflow
by Zacks Equity Research
Hologic (HOLX) introduces features to update Brevera Breast Biopsy System in order to transform patient experience and enhance workflow.
Tandem Diabetes' Advanced Insulin Pump Study Results Favorable
by Zacks Equity Research
Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.
Bruker Rides on MALDI Launches Amid Coronavirus-Led Crisis
by Zacks Equity Research
For higher specific detection of the SARS-CoV-2 virus, Bruker (BRKR) launches luoroType SARS-CoV-2 plus next-generation 6-plex PCR assay.
ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio
by Zacks Equity Research
ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.
Hologic's Acessa Health Buyout to Broaden GYN Surgical Line
by Zacks Equity Research
Hologic's (HOLX) newly-acquired product line is set to complement its market-leading MyoSure products for hysteroscopic removal of fibroids.
Align Technology (ALGN) Strong on Robust Customer Adoption
by Zacks Equity Research
Align Technology (ALGN) treats the one millionth patient from the APAC region, highlighting the Invisalign system's continued adoption.
Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline
by Zacks Equity Research
Bristol Myers (BMY) enters into an agreement to acquire privately-held Forbius in a bid to boost its pipeline of immunotherapies.
Insulet (PODD) Banks on Omnipod Uptake Amid Coronavirus Woes
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Amedisys & BrightStar Ink Agreement to Expand Personal Care
by Zacks Equity Research
Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.
QIAGEN (QGEN) to Launch COVID-19 Antibody Test in the US
by Zacks Equity Research
QIAGEN's (QGEN) latest antibody test complements its array of COVID-19 testing solutions in an economical way to detect immune responses in people who have been exposed to the SARS-CoV-2 virus.
The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed
by Zacks Equity Research
The Zacks Analyst Blog Highlights: QIAGEN, Merit Medical, OPKO, Abbott and Abiomed
Vertex's Triple Combo Cystic Fibrosis Pill Kaftrio Gets EU Nod
by Zacks Equity Research
Vertex's (VRTX) triple combo regimen Kaftrio (ivacaftor/tezacaftor/elexacaftor) secures a nod in Europe to treat the younger lot aged 12 years and above with cystic fibrosis.
ASCO Recommends Myriad Genetics' Test to Treat Ovarian Cancer
by Zacks Equity Research
Myriad Genetics' (MYGN) myChoice CDx test gets included in ASCO's latest recommendations for advanced ovarian cancer patients.
Medtronic's (MDT) Evolut TAVR Label Expansion Gets FDA Nod
by Zacks Equity Research
Medtronic's (MDT) Low Risk Bicuspid Study shows bicuspid patients implanted with Evolut TAVR had low rates (1.3%) of all-cause mortality.
TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle
by Zacks Equity Research
The acquired business of Teleflex (TFX), NeoTract has been performing impressively lately.
Here's Why You Should Hold on to NuVasive (NUVA) Stock Now
by Zacks Equity Research
Investors are optimistic about NuVasive (NUVA) on continued momentum across several recently-launched products as well as potential in its U.S. Surgical Support business.
Medtronic Initiates Post-Market ELITE Study for SNM Therapy
by Zacks Equity Research
Medtronic's (MDT) ELITE study is expected to reinforce long-term safety, efficacy and patient benefit from the SNM therapy.
MedTech Lifts S&P 500 Index: 3 Stocks With Upside Potential
by Urmimala Biswas
MedTech stocks play a major role in holding the index up and ending the shortest bear run in the history of S&P 500.
Albireo (ALBO) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
Albireo (ALBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Medtronic Publishes IN.PACT AV Access Trial Study Results
by Zacks Equity Research
Medtronic's (MDT) IN.PACT AV demonstrates significant reductions in hospital visits for AV fistulae maintenance, which is leading to successful and uninterrupted dialysis of ESRD patients.
Globus Medical Sees Strong Rebound Despite Coronavirus Crisis
by Zacks Equity Research
Globus Medical (GMED) witnesses a significant rebound from mid-April through the remainder of Q2.
7 Top-Ranked Corporate Giants With More Than 50% Return YTD
by Nalak Das
A handful of corporate giants (market capital > $10 billion) have skyrocketed this year, braving the pandemic and its impact on businesses.
QIAGEN Launches Primer Panel for NGS of Coronavirus Genome
by Zacks Equity Research
QIAGEN (QGEN) expands the NGS portfolio with the launch of the genome analyzing panel to support holistic research of the SARS-CoV-2.
Has QIAGEN N.V. (QGEN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
Omnicell (OMCL) Hurt by Coronavirus-Led Lower Product Booking
by Zacks Equity Research
Omnicell (OMCL) is currently witnessing slowdown in purchasing decisions by hospitals.